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Background: Tissue expanders are used in breast reconstruction after mastectomy to stretch the remaining tissue
to create space for placement of permanent breast implants. The AeroForm™ Tissue Expander, developed by
AirXpanders™ Inc., contains electronic components designed to activate the release of carbon dioxide from an
internal reservoir to inflate the expander. Breast cancer patients who undergo mastectomy and tissue expander/
implant-based breast reconstruction may require radiation therapy at doses up to 50–60 Gy while the expander is
in place. The ionizing radiation used in postmastectomy radiation therapy interacts with electronic components in
medical implants, which may cause degradation in performance above certain levels. Most commercial electronic
components used in medical devices, such as complementary metal-oxide semiconductor or bipolar integrated
circuits can withstand radiation levels in the 50 Gy range without any performance degradation. Beyond this level,
the performance may still be sufficient to guarantee functionality, but this needs to be confirmed at the system and
electronic circuit level. We assessed the impact of radiation levels up to 75 Gy on 32 AeroForm™ Tissue Expanders
(AirXpanders, Inc., Palo Alto, CA USA) and on the associated internal printed circuit assemblies.
Findings: The electronics inside the AeroForm™ Tissue Expander implant continued to function properly after
exposure to radiation levels up to 75 Gy, which is well above the maximum total dose level typically used in
postmastectomy radiation therapy.
Conclusions: Standard postmastectomy radiation therapy doses do not damage or affect the functionality of the
AeroForm™ Tissue Expander.
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Background
Following mastectomy, immediate breast reconstruction
is the standard of care in many clinical settings because
of the associated psychological benefits to the patients
[1-3]. Typically, patients who select implant-based breast
reconstruction require expansion of the remaining tissue
with saline expanders, which involves many disruptive
and often painful saline injections over several months
at the surgeon’s office. AirXpanders (AirXpanders, Inc.,
Palo Alto, California USA), in an effort to provide the
patient with a more comfortable, gradual tissue expan-
sion process that they control, has manufactured and is* Correspondence: ahoffman@airxpanders.com
2AirXpanders, Inc, 1047 Elwell Court, Palo Alto, CA 94303, USA
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reproduction in any medium, provided the orinvestigating a breast tissue expansion system consisting
of an implantable tissue expander (AeroForm™) and a
handheld radio-frequency dosage controller. The dosage
controller communicates with the expander and allows
the patient to administer 10 cc doses of CO2 from a res-
ervoir within the expander; pre-clinical and feasibility
studies have been reported [4,5].
Approximately 55% of women with high-risk breast
cancer undergo radiation therapy postmastectomy [6].
Radiation protocols vary but in cases of immediate re-
construction, radiation may be administered during the
reconstruction process with the tissue expander in place.
In light of the fact that AeroForm expansion depends on
the proper functioning of the implant electronics, we
chose to test the electronics of the expander implant
and its printed circuit assemblies (PCAs) in conditions
that simulated as well as exceeded the radiation expos-
ure encountered in a clinical therapeutic setting.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Coupling voltage before irradiation, within
72 hours of irradiation, and 26–30 days after irradiation
Pre-irradiation Immediate Delayed
Mean 1.228 1.210 1.219
σ2 0.027 0.033 0.032
Min 1.18 1.16 1.17
Max 1.32 1.3 1.31
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Radiation parameters
The cumulative doses typically used in postmastectomy
radiation therapy are 50–60 Gy and are administered in
fractions of 1.8-2.5 Gy/day over several weeks to
minimize damage to tissue [7,8]. Modern clinical radio-
therapy utilizes megavoltage X-rays produced by a linear
accelerator with energies typically ranging from 4–20 MV
[9-11]. Prior to the production of these linear accelerators,
Cobalt-60 gamma ray sources were used, which emit
gamma rays with energies of 1.17 MV and 1.33 MV. X-rays
with energy above 5 MV affect silicon devices in a similar
manner as equivalent radiation from Cobalt-60 (Co-60)
gamma rays [12].
Electrical parameters
Threshold voltage (one of the electrical properties of metal-
oxide-semiconductor field-effect transistor (MOSFET) de-
vices) is affected by radiation exposure in a predictable
pattern [13], and indeed MOSFETs have been used as
dosimeters in various medical applications [14]. Threshold
voltage variation is a measure of the impact of radiation on
the tissue expander electronics. In the AeroForm electron-
ics, the threshold voltage of a system-critical MOSFET
(FK390601; Panasonic Corporation, Osaka, Japan) is re-
quired to be greater than 806 mV to guarantee full system
performance, based on various parameters within the elec-
tronics. Analyzing this metric offers an understanding of
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Figure 1 Average percent change (± standard error) in threshold voltProcedure
We contracted a third-party commercial radiation test-
ing laboratory (Aeroflex RAD, Inc., Colorado Springs,
Colorado USA) to perform total ionizing dose (TID)
tests of AeroForm tissue expanders and their PCAs
using a Co-60 radiation source [15]. The dose rate was
6 Gy/minute (600 MU/min) to simulate the highest
commonly used dose rate on commercial linear accelera-
tors. The laboratory exposed test samples in air at differ-
ent increments up to a total clinical dose of 50 Gy plus
increments up to 1.5 times that dose to determine the
total ionizing dose effects on the device’s function and
that of its electronic components. Since little-to-no
“healing” (or annealing) occurs in electronics between
consecutive fractions [16], we considered only total cu-
mulative doses in the test. Total dose was determined by
the amount of time units were exposed at the specified
dose rate. Scattering dose, single-event dose, and transi-
ent dose effects were not considered in this study.
The laboratory exposed four tissue expander test samples
to each of the following seven TID radiation levels: 10 Gy,
20 Gy, 30 Gy, 40 Gy, 50 Gy, 60 Gy and 75 Gy. The lab also
exposed an additional four tissue expanders to 50 Gy, for a
total sample of 32 tissue expanders. In addition to the
expanders, sets of four individual PCAs (totaling 28 PCAs)
were also subjected to the same dose levels.
Prior to irradiation, we tested each tissue expander
and PCA according to the manufacturer’s custom func-
tional test to verify functionality of the products. Testing
involved a comprehensive simulation of patient and
physician use: (1) establish communication between the
dosage controller and the tissue expander as evidenced
by light and sound feedback from the dosage controller,
(2) verify that sufficient coupling strength (coupling volt-
age greater than 1.15 V) can be achieved at a distance of
1–2.5 cm between the dosage controller and the tissue
expander, and (3) verify the delivery of CO2 doses. Test-
ing also measured design-specific parameters such as
time constants, MOSFET threshold voltages, and otherImmediate Delayed
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Figure 2 The average threshold voltage (± standard error) of MOSFET in-circuit.
Rembert et al. Radiation Oncology 2013, 8:235 Page 3 of 4
http://www.ro-journal.com/content/8/1/235voltage and current levels. The test results were used to
assess the margin in system performance given the radi-
ation effects. Throughout the process, the electronics were
handled in an electrostatic discharge (ESD)-safe environ-
ment, using appropriate ESD protection equipment.
The laboratory provided dosimetry information for
each radiated set, and all parts were returned to us
packed in dry ice to prevent any annealing in the compo-
nents during shipping. Upon receipt of the product, we
allowed the samples to return to room temperature and
then repeated the manufacturer’s tests twice for each unit
received: one set of tests was performed within 72 hours
of irradiation (immediate); the other was performed be-
tween 26 and 30 days after irradiation (delayed). The two
sets of tests were identical to the pre-irradiation tests.
Results
Each of the 32 tissue expanders passed all three sets of
functional tests (pre-irradiation, immediate and delayed)
and performed according to product specifications. All
expanders were able to establish communication with
the dosage controller, achieve coupling voltage greater
than 1.15 V (Table 1), and deliver three CO2 doses.



















Figure 3 Correlation between threshold voltage change and radiationwith respect to test or radiation level (two-factor ANOVA,
Ftest = 2.455, p = 0.1278, Flevel = 1.794, p = 0.1830).
Figure 1 shows the percent change in threshold volt-
ages of a MOSFET whose function was an indicator of
system performance on the PCAs, before radiation ex-
posure, within 72 hours post-irradiation, and at 26–
30 days post-irradiation. Figure 2 shows the average
threshold voltage of this MOSFET in-circuit (± standard
error) on an absolute scale (rather than a relative scale).
There were significant effects of test (pre-irradiation, im-
mediate, delayed), and radiation level (two-factor ANOVA,
Ftest = 16.94, p = 0.0003, Flevel = 3.8457, p = 0.0225). Thresh-
old voltages showed a statistically significant decrease after
radiation exposure (paired t-test for means, t = 3.8552,
p = 0.0084), but did not continue to change between the
first and second post-irradiation tests (paired t-test for
means, t = 1.6859, p = 0.1428).
A fair degree of component-to-component variation in
threshold voltage was evident; however, in all cases, the
threshold voltage remained well above the minimum the-
oretical voltage to maintain system functionality post-
irradiation (806 mV). Of note, the manufacturer of this
MOSFET guarantees an initial threshold voltage of 0.9 V–
1.5 V under normal conditions, and the initial thresholdy = -0.001073x 
R  = 0.959500 
50 60 70 80 90 100 
n Dose (Gy) 
dose.
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of the guaranteed range. In a theoretical worst-case sce-
nario, where the highest observed percent change
(−9.091%, observed at 75 Gy) would occur in a component
whose threshold voltage starts at 0.9 V, the resulting
threshold would still be above the minimum allowable
(818 mV vs. 806 mV). The worst-case scenario at 50 Gy
(−5.505% drop) would exhibit a 5.2% margin (850 mV vs.
806 mV).
There was a strong linear correlation between threshold
voltage change and radiation dose (R2 = 0.9595, slope =
−0.1073% per Gy, assuming y-intercept at zero) (Figure 3).
The theoretical maximum radiation dose under which the
system would maintain functionality is 97.34 Gy, as ex-
trapolated from the slope in the figure and assuming a
worst-case initial threshold voltage of 0.9 V (percent
change from 0.9 V = (0.806-0.9)/0.9 = −0.001073*97.34).
Discussion
The AeroForm tissue expanders and associated electron-
ics performed to their specified functionality when tested
under simulated harsh radiation environments. The first
test, performed within 72 hours of irradiation, provided
a worst-case scenario measurement, while the second
test, performed 26–30 days after irradiation, more closely
represented typical clinical use wherein the patient would
resume tissue expansion several weeks after undergoing
radiation therapy. The described functional testing and re-
sults predicate successful operation of the AeroForm tis-
sue expander in patients undergoing postmastectomy
reconstruction with adjuvant radiation therapy.
The results of this testing are not intended as a recom-
mendation for the use of radiation therapy in patients with
an implanted tissue expander. The decision regarding ra-
diation therapy in patients with a tissue expander in place
should be made by the surgeon and radiation oncologist.
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